First U.S. Patient Enrolled in Cardionomic’s CPNS Pilot Study

November 2, 2021

Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial U.S. enrollment in their global Cardiac Pulmonary Nerve Stimulation (CPNS) Pilot Study (NCT04814134). The study is evaluating the safety and performance of the CPNS System in patients suffering from acute decompensated heart failure (ADHF), defined as new or worsening symptoms of heart failure. The first U.S. patient was enrolled and implanted at The Ohio State University Wexner Medical Center in Columbus, OH by Principal Investigator, Dr. Sitaramesh Emani, assisted by Dr. Rami Kahwash.

Cardionomic Announces First Patients Enrolled in CPNS Pilot Study

April 5, 2021

Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study. The study will evaluate the safety and performance of the CPNS in patients suffering from Acute Decompensated Heart Failure, defined as new or worsening symptoms of heart failure. The first patients were enrolled by Temistocles Díaz, M.D., Principal Investigator at Pacifica Salud Hospital Punta Pacifica in Panama City, Panama. He was joined by Co-Investigators Thais Coronado, M.D. and Jose Pinto, M.D. Up to fifty patients are expected to be enrolled worldwide.

Cardionomic raises $20 million in series a financing to develop heart failure therapy 

October 26, 2015

MINNEAPOLIS – Oct. 26, 2015 – Medical device developer Cardionomic, Inc., today announced that it has received $20 million in Series A financing. Investors include New Enterprise Associates (NEA), the Cleveland Clinic, Greatbatch Inc., and others.